Where does Roel Bulthuis work?

Roel Bulthuis is Managing Partner at Syncona and Board director at Ambagon Therapeutics and Board director at Quralis.

What does Roel Bulthuis invest in?

Roel Bulthuis invests in Biotech.

What check size does Roel Bulthuis write?

Roel Bulthuis typically writes checks of $100K – $5M.

What boards does Roel Bulthuis sit on?

Roel Bulthuis holds tracked board seats at Ambagon Therapeutics, Anaveon, iOnctura, Quralis, Re-Aim Therapeutics, Resolution Therapeutics.

Where did Roel Bulthuis go to school?

Roel Bulthuis studied at Helsingin kauppakorkeakoulu (MBA, Finance); Leiden University (Msc, Biopharmaceutical Sciences).

Roel Bulthuis

Investor

Managing Partner at Syncona · Board director at Ambagon Therapeutics · Board director at Quralis

Amsterdam, Netherlands

Writes $100K – $5M checks · typically $1.5M

About

Roel Bulthuis is a Managing Partner at Syncona, where he leads the investment team and draws on over 20 years of experience in life science venture capital, business development, and investment banking. He previously served as Managing Partner and head of healthcare at Inkef Capital, and before that as SVP and Managing Director of Merck Group's M-Ventures, following senior business development roles at Merck Serono and a position in investment banking at Fortis Bank. He holds an MSc in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics, and is a Kauffman fellow and Level20 mentor.

Invests in

Biotech

Board director at Ambagon Therapeutics

Intro paths

→

In turn, Roel can intro founders to Ambagon Therapeutics's investors below.

Ambagon Therapeutics's investors · 7

Droia VenturesLeuven · $540K checks · since 2021 InkefAmsterdam · since 2025 Mission BiocapitalSan Francisco · $500K checks · since 2025 MRL Ventures FundCambridge · $25M checks · since 2025 Nextech InvestZurich · $648K – $3.2M checks · since 2025 RA CapitalBoston · since 2025 SynconaLondon · since 2022

Co-founders at Ambagon Therapeutics

Christian OttmannExecutive Officer

Board director at Quralis

Intro paths

→

In turn, Roel can intro founders to Quralis's investors below.

Quralis's investors · 10

Dolby Family VenturesSan Francisco Droia VenturesLeuven · $540K checks · since 2025 InkefAmsterdam MC Healthcare VenturesCambridge Mission BiocapitalSan Francisco · $500K checks · since 2025 Mitsui Global InvestmentMenlo Park · $500K – $10M checks Polaris PartnersBoston · $500K – $5M checks · since 2025 Sanofi VenturesCambridge · $5M checks SV Health InvestorsBoston · $1M – $20M checks SynconaLondon · since 2022

Co-founders at Quralis

Kevin EgganCo-founder

RoetCo-founder

WoolfCo-founder

Kasper RoetDirector, Executive Officer, Promoter

Experience

Syncona LimitedManaging Partnercurrent2023 — presentGreater London, England, United Kingdom
1 bike, 2 bikes, 3 bikesEnjoying the sun2023
INKEF CapitalManaging Director2019 — 2023The Randstad, Netherlands
M VenturesSenior Vice President & Managing Director2015 — 2018The Randstad, Netherlands
M VenturesSenior Vice President & Managing Director2009 — 2018The Randstad, Netherlands
Merck SeronoSenior Director, Head of Merck Serono Ventures2009 — 2015
Merck SeronoDirector, Head of Venture Capital Scouting2007 — 2009
Serono InternationalAssociate Director, Corporate M&A2006 — 2007
Fortis BankDirector-Biotechnology Investment Banking2000 — 2005
DevgenBusiness Development2000

Deals · 2

QuralisBoard seat

via Syncona · filed Sep 2022 · $10M raise

Ambagon TherapeuticsBoard seat

via Syncona · filed Jun 2022 · $85M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Anaveon iOncturaRe-Aim TherapeuticsResolution Therapeutics

Sources: SEC Form D filings · the firm's website.

Colleagues at Syncona

Anastasia Prechistenskaya

Frequently asked questions

Who is Roel Bulthuis?: Roel Bulthuis is a Managing Partner at Syncona, where he leads the investment team and draws on over 20 years of experience in life science venture capital, business development, and investment banking. He previously served as Managing Partner and head of healthcare at Inkef Capital, and before that as SVP and Managing Director of Merck Group's M-Ventures, following senior business development roles at Merck Serono and a position in investment banking at Fortis Bank. He holds an MSc in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics, and is a Kauffman fellow and Level20 mentor.
Where does Roel Bulthuis work?: Roel Bulthuis is Managing Partner at Syncona and Board director at Ambagon Therapeutics and Board director at Quralis.
What does Roel Bulthuis invest in?: Roel Bulthuis invests in Biotech.
What check size does Roel Bulthuis write?: Roel Bulthuis typically writes checks of $100K – $5M.
What boards does Roel Bulthuis sit on?: Roel Bulthuis holds tracked board seats at Ambagon Therapeutics, Anaveon, iOnctura, Quralis, Re-Aim Therapeutics, Resolution Therapeutics.
Where did Roel Bulthuis go to school?: Roel Bulthuis studied at Helsingin kauppakorkeakoulu (MBA, Finance); Leiden University (Msc, Biopharmaceutical Sciences).